Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
U.S. FDA
Pharma
Priovant secures 1st FDA nod in rare skin and muscle disease
Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing the asset its first nod in a rare skin disease.
Fraiser Kansteiner
Aug 27, 2026 9:30pm
Gilead crosses FDA finish line with new HIV combo pill
Aug 27, 2026 5:56pm
FDA weighs new drug, tech deputy commissioner posts: report
Aug 26, 2026 9:45am
Hansa eyes US listing ahead of FDA verdict on Idefirix
Aug 24, 2026 2:45pm
Xspray's Dasynoc knocked back by FDA over production once again
Aug 20, 2026 2:50pm
B. Braun launches IV solution recall over particle concerns
Aug 20, 2026 10:44am
